(Q35917226)

11 August 2017

1 reference

title

Moxifloxacin (Avelox): a novel fluoroquinolone with a broad spectrum of activity (English)

1 reference

11 August 2017

1 reference

Juan-Pablo Caeiro

1

1 reference

11 August 2017

Paul B Iannini

series ordinal

2

1 reference

11 August 2017

publication date

1 October 2003

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

1

1 reference

11 August 2017

issue

3

1 reference

11 August 2017

page(s)

363-370

1 reference

Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Maintaining fluoroquinolone class efficacy: review of influencing factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Fluoroquinolones: action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory se

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

The role of fluoroquinolones in skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Reassuring safety profile of moxifloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Fluoroquinolones and risk of Achilles tendon disorders: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Achilles tendon disease in lung transplant recipients: association with ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Widespread use of fluoroquinolones versus emerging resistance in pneumococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.1.3.363

21 January 2018

Identifiers

DOI

10.1586/14787210.1.3.363

1 reference

11 August 2017

1 reference